In a significant boost for the European biotechnology landscape, Barcelona-based Ona Therapeutics has successfully closed an $86.6 million Series B funding round. This capital infusion marks a pivotal transition for the startup, which is now poised to move two of its lead antibody-drug conjugate (ADC) candidates into clinical development. With a mission to address the intractable problem of drug resistance in cancer, Ona is positioning itself as a key player in the next generation of precision oncology.
The Evolution of the ADC Landscape
To understand the significance of Ona Therapeutics’ latest milestone, one must first recognize the paradigm shift currently occurring in oncology. Antibody-drug conjugates—often described as "biological missiles"—have fundamentally altered the standard of care for numerous malignancies. By tethering a potent cytotoxic agent to a monoclonal antibody that specifically seeks out tumor-associated antigens, researchers have created therapies that can deliver lethal doses of chemotherapy directly to cancer cells while sparing healthy tissue.
The success of blockbuster drugs like AstraZeneca and Daiichi Sankyo’s Enhertu has validated the ADC platform as a multibillion-dollar commercial reality. Enhertu, in particular, has rewritten the prognosis for patients with HER2-positive breast cancer, demonstrating efficacy that has allowed it to move into earlier lines of treatment.
However, the field is far from stagnant. While early ADCs focused on high-expression targets—antigens found in massive quantities on the surface of tumor cells—the "low-hanging fruit" has largely been harvested. Newer biotechs are now racing to refine the technology, experimenting with novel linkers to improve stability, exploring bispecific antibodies that hit two targets simultaneously, or employing protein degraders to dismantle cancer-driving mechanisms from within.
Ona Therapeutics: A Strategic Pivot
Ona Therapeutics’ approach differentiates itself through a sharp focus on the root cause of treatment failure: resistance. Under the leadership of CEO Valerie Vanhooren, the company initially explored standard monoclonal antibodies. However, internal research revealed that these therapies, while groundbreaking in their own right, often lacked the sheer "killing power" required to eradicate the resilient, metastatic cells that eventually lead to patient relapse.
"If we can tackle those cells responsible for resistance, you can have a deeper response and you can give these patients a longer quality of life," Vanhooren stated in an interview.
The company’s strategy involves identifying novel, highly specific targets that are highly expressed in cancer cells but remain "barely detectable" in healthy tissue. By avoiding the common issue of off-target toxicity, Ona believes it can push the therapeutic window further than existing options.
Chronology of Development: From Series A to Clinical Readiness
Ona’s trajectory reflects the methodical, high-stakes nature of modern drug development:
- 2020: The Foundation. The company launched with a €30 million (approx. $34 million) Series A round. This capital allowed the team to build out its preclinical pipeline and validate the target identification platform.
- 2020–2024: The Preclinical Grind. During this period, the team focused on refining the payload and linker technologies, ensuring that their candidates, ONA-255 and ONA-389, were robust enough for regulatory scrutiny.
- 2024: The Series B Catalyst. With $86.6 million in fresh funding—co-led by Columbus Venture Partners and Mérieux Equity Partners—the company is now shifting its infrastructure toward human trials. The inclusion of eight additional investment firms underscores a strong venture capital consensus on the viability of their science.
Lead Assets and Target Populations
The company’s primary focus is ONA-255, an ADC currently being developed for third-line treatment of hormone receptor-positive (HR+), HER2-negative metastatic breast cancer. This patient population represents the largest subset of metastatic breast cancer cases—roughly 73%.
Currently, patients in this cohort rely on endocrine therapies and CDK 4/6 inhibitors. While these drugs effectively manage the disease for a time, resistance is almost inevitable. Once these lines of therapy are exhausted, the clinical landscape becomes sparse.
"There are not novel targets and not novel treatments there," Vanhooren noted. By aiming for this specific "post-treatment" vacuum, Ona is attempting to provide a lifeline for patients who have few, if any, alternatives.
The company is also working on a second prospect, ONA-389, which targets the same unidentified protein but is intended for colorectal cancer. By utilizing a "platform" approach where one target can be addressed across different solid tumor types, Ona hopes to maximize the efficiency of its clinical trial spend.
Industry Expertise: The Board’s Strategic Influence
A biotech company is only as good as the wisdom guiding its board of directors. Ona has secured an enviable roster of industry veterans to steer its development strategy.
Among its board members are Antoine Yver, a luminary in the ADC field who played a critical role in the development of Enhertu at AstraZeneca/Daiichi Sankyo, and Pamela Klein, a veteran of Genentech who was instrumental in the clinical success of landmark drugs like Herceptin and Rituxan. This level of oversight suggests that Ona is not just a scientific project, but a commercially oriented entity with a clear roadmap toward regulatory approval and market entry.
Implications for the Future of Oncology
The success of Ona Therapeutics’ funding round highlights a broader trend: the venture capital market remains deeply invested in "next-wave" oncology. As traditional chemotherapies are replaced by targeted biological agents, companies that can prove they have solved the issue of resistance will command premium valuations and, more importantly, reshape the patient experience.
Challenges Ahead
Despite the optimism surrounding the Series B, the path forward is fraught with hurdles. Clinical trials for ADCs are notoriously complex. Investigators must carefully manage the delicate balance between payload potency and systemic toxicity. Furthermore, identifying the right patient population—those whose tumors specifically express the "Ona-target"—will require the development of highly accurate companion diagnostics.
If Ona can successfully navigate the transition to human studies, they could prove that targeting the "hard-to-find" antigens is a viable strategy for overcoming therapy resistance. This would provide a blueprint for other companies struggling with the same fundamental limitation in solid tumor treatment.
Conclusion
With $86.6 million in the bank and a leadership team seasoned by the industry’s most successful oncology breakthroughs, Ona Therapeutics is well-positioned to move out of the laboratory and into the clinic. Their work does not merely aim to add another drug to the oncology shelf; it aims to change how we think about the life cycle of a cancer cell.
By focusing on the mechanisms of resistance rather than just the primary tumor bulk, Ona is addressing one of the most critical challenges in modern medicine. As they prepare to take ONA-255 into human trials, the oncology community will be watching closely to see if this Barcelona-based startup can turn its sophisticated science into a durable, life-extending reality for patients with few remaining options.
About the Author
